Immune System Disorder (Healthy Volunteer) Clinical Trial
Official title:
A Phase 1, Placebo-Controlled, Double-Blind Study to Examine the Safety, Tolerability, and Pharmacokinetics of 500 mg KD025 Administered Twice Daily in Healthy Male and Post-Menopausal Female Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.
Up to approximately 58 days including safety follow up period of 30 days after participant is treated with the last dose of study drug. ;